Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol. 2021 Oct 20;39(30):3352-3363. doi: 10.1200/JCO.21.00917. Epub 2021 Aug 31.
J Clin Oncol. 2021.
PMID: 34464155
Free PMC article.
Clinical Trial.
Effects of nanocurcumin supplementation on T-helper 17 cells inflammatory response in patients with Behcet's disease: a randomized controlled trial.
Farzaneh R, Khabbazi A, Soltani-Zangbar MS, Abbasian S, Malek Mahdavi A, Motavalli R, Yousefi M.
Farzaneh R, et al.
Immunopharmacol Immunotoxicol. 2022 Apr;44(2):206-215. doi: 10.1080/08923973.2022.2026380. Epub 2022 Jan 12.
Immunopharmacol Immunotoxicol. 2022.
PMID: 35021944
Clinical Trial.
Item in Clipboard
Nanocurcumin supplementation ameliorates Behcet's disease by modulating regulatory T cells: A randomized, double-blind, placebo-controlled trial.
Abbasian S, Soltani-Zangbar MS, Khabbazi A, Farzaneh R, Malek Mahdavi A, Motavalli R, Hajialilo M, Yousefi M.
Abbasian S, et al.
Int Immunopharmacol. 2021 Dec;101(Pt B):108237. doi: 10.1016/j.intimp.2021.108237. Epub 2021 Oct 12.
Int Immunopharmacol. 2021.
PMID: 34653732
Clinical Trial.
Item in Clipboard
Cite
Cite